CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To analyze cerebrovascular accidents (CVAs) pooled from large, randomized, controlled clinical trials of ranibizumab treatment for neovascular age-related macular degeneration. Methods: Events in five trials (FOCUS, MARINA, ANCHOR, PIER, and SAILOR) were analyzed using a standard safety monitoring process. Exact methods, stratified by study, were used to test for treatment differences based on odds ratios. A stepwise logistic regression model was fit to classify subjects' risk for CVA based on medical history. Treatment differences in CVA rates at 1 year or 2 years were evaluated within risk groups using stratified exact methods. Results: Pooled 2-year CVA rates were <3%; odds ratios (95% confidence intervals) for CVA risk were 1.2 (0.4–4.4) for ranibizumab 0.3-mg versus control, 2.2 (0.8–7.1) for 0.5 mg versus control, and 1.5 (0.8–3.0) for 0.5-mg versus 0.3-mg ranibizumab. No substantial increased risk of CVA for 0.5 mg versus 0.3 mg was identified in pooled analyses or any of the individual trials. In pooled analyses, the difference between 0.5-mg ranibizumab and control was larger (7.7 [1.2–177]) among high-risk CVA patients. Conclusion: This analysis provided some evidence, although not definitive, of a potential increased risk of CVA with ranibizumab versus control or with 0.5-mg versus 0.3-mg ranibizumab. Continued monitoring for CVA within clinical trials seems warrented. This analysis provided some evidence, although not definitive, of a potential increased risk of cerebrovascular accident with ranibizumab versus control or with 0.5-mg versus 0.3-mg ranibizumab. Continued monitoring for cerebrovascular accident within clinical trials seems warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Self-citationHeier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
Cited by
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Age-Related Macular Degeneration
Thomas, C. J., Mirza, R. G., & Gill, M. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.01.003 · Cited by 399
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Le, K., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305252 · Cited by 382
Diabetic retinopathy: pathogenesis, clinical grading, management and future developments
Heng, L. Z., Comyn, O., Peto, T., Tadros, C., Ng, E., Sivaprasad, S., & Hykin, P. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12089 · Cited by 285
Metadata
- Authors
- Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., & Rubio, R. G.
- Venue
- Retina
- Published
- 2012-10
- Volume
- 32
- Issue
- 9
- Pages
- 1821-1828
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1968427420
- Cited by
- 88
- References
- 4
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS. https://app.cochat.ai/papers/10.1097/iae.0b013e31825db6ba
- The paper
- Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., & Rubio, R. G. (2012). CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS. Retina. https://doi.org/10.1097/iae.0b013e31825db6ba
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.